ERBB2 knockdown was generated in target cells through the transfection of
si-ERBB2 synthesized by GenePharma (Shanghai, China). Ascramble sequence (si-NC) was used as anegative control. miR-488 overexpression or inhibition was generated in target cells by the transfection of miR-488 mimics or inhibitors synthesized by GenePharma. Regarding NFκB1 overexpression, the full-length human RELA cDNA was cloned in pcDNA3.1 expression vector using ahomologous recombination method. The empty vector pcDNA3.1 was used as anegative control. For cell transfection, 1 × 10
5 cells were seeded in a6-well cell culture plate, 24 h later, cells were transfected with 50 pmol final concentration miR488-5p mimics, miR488-5p inhibitor or
si-ERBB2 through 5 μl per well
lipofectamine 3000 (Invitrogen). Following incubation with the RNA
lipofectamine 3000 complex for 6 h, cells were further cultured with fresh complete medium for 48 h and harvested for further laboratory analysis. The sequence of siRNAs and primers for plasmid construction are listed in Table S1.
Han D., Zhu S., Li X., Li Z., Huang H., Gao W., Liu Y., Zhu H, & Yu X. (2022). The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling. Cancer Biology & Therapy, 23(1), 294-309.